In addition, a phase III clinical trial (NCT04303780, Table 2) is currently underway for comparing the efficacy of sotorasib and docetaxel in patients with NSCLC with KRAS G12 mutation before treatment. Here, KRAS is linked to non-small cell lung carcinoma.